RemeGen Co., Ltd. (OTCMKTS:REGMF) Sees Large Drop in Short Interest

RemeGen Co., Ltd. (OTCMKTS:REGMF) was the recipient of a significant decline in short interest in January. As of January 15th, there was short interest totalling 500,000 shares, a decline of 42.2% from the December 31st total of 864,500 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is currently ∞ days.

RemeGen Price Performance

Shares of OTCMKTS:REGMF remained flat at $1.50 during midday trading on Wednesday. RemeGen has a twelve month low of $1.50 and a twelve month high of $4.00. The company’s 50 day simple moving average is $1.50 and its 200 day simple moving average is $1.67.

RemeGen Company Profile

RemeGen Co, Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers.